One Simple Chart to Note Before Next Week
Recap - The markets have rebounded precipitously from lows this October, with both the S&P 500 and iShares NASDAQ Biotechnology Index (IBB) making new all-time highs in the … Continue Reading
Read nowSearch Results for endo health
Recapping Our Top Trades & Stories in Biotech
Recap - Johnson & Johnson (JNJ) is shelling out $1.75 billion to acquire Alios Biopharma, a private developer of therapeutics for viral diseases. Alios’ lead drug asset … Continue Reading
Read now
Buyers are Supposedly Circling InterMune: Here’s Our Take
Research - InterMune’s (ITMN) stock rose 14 percent last Wednesday, closing at a 14-year high of $52.06, on rumors that big pharma is lining up to bid for … Continue Reading
Read now
Coming Up: Make or Break for Amicus’ Pharmacological Chaperone Technology
Research - Amicus Therapeutics (FOLD), with a current market value of just $271 million, represents a high-risk, high reward play for investors willing to bet that the … Continue Reading
PremiumOne Heckuva Win for Readers this Week
Recap - Great news for longtime PropThink readers on Monday morning – BioDelivery Sciences (BDSI) announced positive results from the second of two phase 3 studies testing BEMA-Buprenorphine in chronic pain … Continue Reading
Read now
On Sourcing Investment Ideas and A Few Simple Growth Criteria
Insights - Determining the attractiveness of a revenue-generating company vs. a development-stage opportunity varies tremendously in healthcare, but there are a few quantitative metrics that can be used … Continue Reading
Read now
More Money! Why Tekmira is Worth Revisiting
Research - -TKMR remains an interest at PropThink despite rising 260% since coverage in January. Stock is undervalued relative to peers, has an expanding pipeline, and is … Continue Reading
Read now